- Sector
- Healthcare
- Industry
- Biotechnology
Highlights
- EPS (TTM)
- -$16.05
- Gross Profit (TTM)
- -$1.11K
- EBITDA (TTM)
- -$5.04M
- Year Range
- $4.32 - $16.92
- ROA (TTM)
- -45.26%
- ROE (TTM)
- -84.99%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
DCOY Performance Chart
Loading charts...
Returns By Period
Decoy Therapeutics Inc
- 1D
- -4.76%
- 1M
- -17.81%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
DCOY Monthly Returns History
Based on dividend-adjusted daily data since Jan 7, 2026, DCOY's average daily return is +0.04%, while the average monthly return is -2.54%.
Historically, 33% of months were positive and 67% were negative. The best month was May 2026 with a return of +47.4%, while the worst month was Jun 2026 at -32.7%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 3 months.
On a daily basis, DCOY closed higher 45% of trading days. The best single day was Jan 13, 2026 with a return of +53.4%, while the worst single day was Jan 14, 2026 at -30.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.19% | -11.66% | -20.09% | -7.36% | 47.44% | -32.74% | -29.18% |
Benchmark Metrics
Decoy Therapeutics Inc has an annualized alpha of -9.75%, beta of 1.53, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since January 07, 2026.
- This stock captured 378.88% of S&P 500 Index gains and 361.83% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -9.75%
- Beta
- 1.53
- R²
- 0.03
- Upside Capture
- 378.88%
- Downside Capture
- 361.83%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Decoy Therapeutics Inc (DCOY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DCOY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | — | 1.32 | — |
| Calmar ratioReturn relative to maximum drawdown | — | 2.46 | — |
| Martin ratioReturn relative to average drawdown | — | 10.92 | — |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Decoy Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Decoy Therapeutics Inc was 70.60%, occurring on May 15, 2026. The portfolio has not yet recovered.
The current Decoy Therapeutics Inc drawdown is 60.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -70.60%May 2026 | 4mo 1d | — | 5mo 11dJan 2026 - now |
2026 pullback2026 | -8.33%Jan 2026 | 0s | 5d | 5dJan 2026 - Jan 2026 |
Drawdown Indicators
| DCOY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -70.60% | -56.78% | -13.82% |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -60.00% | -3.21% | -56.79% |
Average DrawdownAverage peak-to-trough decline | -49.61% | -10.71% | -38.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 2.04% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Decoy Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Decoy Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with DCOY
Add Decoy Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with DCOY